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CERN, Geneva, Switzerland
State-of-the-art techniques derived from particle accelerators, detectors, and physics 
computing are routinely used in clinical practice and medical research centers: from 
imaging technologies to dedicated accelerators for cancer therapy and nuclear medicine, 
simulations, and data analytics. Principles of particle physics themselves are the founda-
tion of a cutting edge radiotherapy technique for cancer treatment: hadron therapy. This 
article is an overview of the involvement of CERN, the European Organization for Nuclear 
Research, in medical applications, with specific focus on hadron therapy. It also presents 
the history, achievements, and future scientific goals of the European Network for Light 
Ion Hadron Therapy, whose co-ordination office is at CERN.
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iNTRODUCTiON
Physics underpins many techniques and technologies that are used for both diagnosis and treatment 
of a variety of diseases: discoveries from basic physics research have been closely linked to medicine 
for centuries, and numerous tools developed by physicists to pursue their scientific goals have found 
their way into hospitals around the world.
In particular, innovative ideas and technologies originating from particle physics have been play-
ing an increasingly important role in medicine over the last 100 years since the advent of radiation-
based medical diagnosis and treatment. Nowadays, state-of-the-art techniques derived from particle 
accelerators, detectors, and physics computing are routinely used in clinical practice and medical 
research centers: from technology for Positron Emission Tomography (PET) scanners, to dedicated 
accelerators for cancer therapy, simulations, and data analytics.
Hadron therapy, also known as particle therapy, epitomizes the connection between basic physics 
(the property of particles traversing matter) and medicine (cancer treatment). Using protons and 
other ions to treat cancer demands large accelerators; this links radiation therapy to the development 
of increasingly powerful accelerators for particle physics research. At the same time, hadron therapy 
is a truly multidisciplinary venture that requires input from oncologists, radiation biologists, medical 
physicists, particle physicists, and computing scientists.
CERN, the European Organization for Nuclear Research (Figure 1) is the world’s largest particle 
physics laboratory. Its contribution to particle physics research and related technologies has been 
outstanding since its establishment in 1954. CERN’s primary mission is basic research in particle 
physics; yet, the laboratory seeks possibilities to transfer its know-how and technology to other fields, 
including health, in order to maximize the societal impact of its research.
In this context, the European Network for Light Ion Hadron Therapy (ENLIGHT) was launched 
at CERN in 2002, to connect research centers, institutions, and scientists, involved in the research, 
promotion, and realization of hadron therapy in Europe.
This article briefly recaps the history of medical applications at CERN and then provides an 
overview of the present situation, with particular emphasis on research and development connected 
to hadron therapy. The role of ENLIGHT and its research program are also covered.
FiGURe 1 | The Large Hadron Collider (LHC). CERN’s flagship project, 
the LHC is a 27-km circular accelerator where protons collide at a 
center-of-mass energy of 13 TeV. The initial 3-year LHC run, which began 
with a collision energy of 7 TeV, rising to 8 TeV, led to the discovery of the 
Higgs boson in 2012.
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FROM PARTiCLe PHYSiCS TO HeALTH
Fundamental research in particle physics not only pushes back 
the boundaries of our knowledge of the Universe but also cata-
lyzes innovative technology developments: frontier instruments 
like the Large Hadron Collider (LHC) and its detectors require 
technologies and performance that exceed the available industrial 
know-how.
The three technology pillars of particle physics – accelerators, 
detectors, and computing tools – have all found their way into 
the medical field. Accelerators have been used for radiation 
therapy of cancer for decades. Medical applications of particle 
detectors are epitomized by PET, which is a direct application 
of light-sensing techniques. Data handling and simulation tools 
developed by physicists have found use in the biomedical field, for 
example, in establishing personalized treatment plans.
A host of highly specialized technologies is associated with 
each of the three pillars. To transfer this wealth of know-how to 
medicine, it is essential not only to identify which technologies 
are potentially interesting for medical applications but also what 
is their relevance for the medical community. In order to maxi-
mize the societal benefit from particle physics, the physicists’ and 
medical doctors’ research activities should be harmonized. This 
can only be achieved through multidisciplinary networks and 
collaborations, where scientists of different specialties all make 
their contributions to establish a common roadmap. Physicists, 
engineers, and computer scientists would share their knowledge 
and technologies, thus giving first-hand information to the medi-
cal community on the latest technical progress; conversely, doc-
tors and biologists would present their needs and vision for the 
medical tools of the future, thus triggering breakthrough ideas 
and technical developments in specific areas.
Experience gained in particle and accelerator physics may serve 
more than just a technology, which shapes up the medicine of 
the future. Scientific collaborations in particle physics have been 
bringing together thousands of scientists from every corner of the 
world to work on the largest and most complex experiments ever 
conducted by mankind. Collaboration has become second nature 
of particle physicists, who have learned to work collectively on a 
common goal and who rely on mutual consensus to make decisions. 
The collaborative model of particle physics, represented in litera-
ture (1) has been translated into a flexible yet effective management 
structure for the experiments. This new paradigm for teamwork 
has proven its worth, and could serve as a model to follow for the 
emerging multidisciplinary ventures in medical applications.
CeRN and Medical Applications: A Brief 
History
Over the past 60 years, CERN has developed a world-renowned 
expertise in the three core technology domains of particle phys-
ics – accelerators, detectors, and large-scale computing – as well 
as in many ancillary technologies. The transfer of technology and 
know-how has always been one of the missions of the Laboratory, 
even before the formal establishment of a technology transfer unit 
in the late 80s. Early medical applications activities date back to 
the 1970s and have been initiated mostly by individual interests.
The multi-wire proportional chamber conceived in 1968 by 
the CERN physicist Georges Charpak not only opened a new 
era for particle physics and earned its inventor the 1992 Nobel 
Prize in Physics but also found important applications in biology, 
radiology, and nuclear medicine (2, 3).
In 1975, the CERN physicist David Townsend in collaboration 
with the University of Geneva and the Geneva Cantonal Hospital 
made important contributions to the reconstruction of PET 
images and to the development of 3D PET (4–6).
After these individual efforts, CERN witnessed the first 
collaborative endeavors in medical applications in the 90s. A 
partnership was established with TERA Foundation (Italy), 
MedAustron (Austria), and Onkologie 2000 (Czech Republic) 
to initiate the Proton Ion Medical Machine Study (PIMMS). The 
PIMMS study is tightly connected to the birth of the ENLIGHT 
network for hadron therapy in 2002.
In the same years, both the Medipix (7) and Crystal Clear (8) 
collaborations began exploring possible medical applications of 
technologies developed for the LHC detectors (hybrid silicon 
pixel detectors and scintillating crystals, respectively). The Crystal 
Clear Collaboration developed various PET scanners with vari-
able geometry suitable for both small and large animals. One of 
them became commercially available to customers worldwide.
Emerging interest in theranostics, i.e., the possibility to per-
form both imaging and treatment at the same time, has brought 
radioisotopes for medical use under the spotlight. For the past 
50 years, CERN has been hosting ISOLDE, a facility dedicated 
to the production of a large variety of radioactive ion beams for 
different experiments in the fields of nuclear and atomic phys-
ics, solid-state physics, materials science, and life sciences. Over 
1,200 radioisotope beams of more than 70 chemical elements 
have been made available for fundamental and applied research, 
including in the medical field. A particular achievement was the 
demonstration of the efficiency of 149Terbium, one of the lightest 
alpha emitters, for treatment at the level of single cancer cells (9).
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The CeRN Medical Applications Office
For several decades, there have been highly successful individual 
“pockets” of medical technology developments going on at CERN, 
as well as in the physics communities that have strong formal 
collaborations with the laboratory. These efforts had considerable 
success, and the CERN researchers have also been playing key roles 
in various international multidisciplinary collaborations and net-
works in specific fields (such as medical imaging, hadron therapy, 
radioisotopes, data analytics and handling, medical simulations). 
But a profound shift in the global approach of the laboratory to 
the whole issue of knowledge transfer to healthcare was needed.
The laboratory shifted a gear in January 2014 by establishing 
the CERN Medical Applications (CMA) office (10) with the fol-
lowing main goals:
•	 identify, make available, and foster the applicability of the 
CERN’s core technologies in accelerators, detectors, sim-
ulation, large-scale computing, and data handling that are 
pertinent to medical applications;
•	 co-ordinate and structure related activities within the 
organization;
•	 catalyze collaborations with external partners, including 
industry, in a concerted manner.
For the first time in the history of the laboratory, a small amount 
of “seed” funding and manpower resources for medical applica-
tions activities was assigned in the Medium Term (5 year) Plan.
The challenge and aim for the CMA Office is to ensure that 
state-of-the-art technologies and know-how developed at CERN 
are used or modified to provide clinical applications that are 
valuable for the medical community. In order to achieve this 
goal, the laboratory must prioritize its R&D program for medical 
applications according to the main concerns and needs of doc-
tors. At the same time, resources for this program should be 
allocated without compromising particle physics research, which 
is the core mission of CERN. This process requires the input and 
guidance of external experts from various disciplines. In keeping 
with the tried and tested CERN practice, an advisory committee 
composed of external experts was formed. The committee, called 
the International Strategy Committee (ISC), comprises special-
ists from a wide range of medical fields as well as from medical 
physics. Internally, the Head of the CMA Office is assisted by 
the CERN Medical Applications Steering Group (CMASG), 
comprised CERN scientists leading CERN’s projects in the field, 
as well as of experts from the CERN Knowledge Transfer group 
and the CERN EU office.
As a first step, the CMA Office identified the key medical 
physics activities that were already ongoing or were just starting. 
They included a variety of topics: tools for data handling and data 
analytics, detectors for medical imaging, radiation dosimetry 
instruments and techniques, novel accelerators for optimized 
cancer treatment, facilities for researching new radioisotopes 
or for biomedical studies, and the vast realm of non-cancer 
applications.
The ultimate scientific goal of the CMA program is to provide 
more reliable, more efficient, and more cost-effective treatment 
options, as well as to ensure early diagnosis of serious illnesses.
PARTiCLe THeRAPY
The idea of using accelerated beams of protons for cancer treat-
ment was proposed by a visionary physicist and founder of 
Fermilab, Robert Wilson in 1946 (11). Protons and light ions 
have unique physical properties. They penetrate a patient with 
minimal lateral diffusion, depositing most of their energy at the 
end of their range (in the so-called Bragg peak), effectively spar-
ing healthy tissue on their way to the tumor. In addition, they can 
be focused into narrow pencil beams allowing a precise radiation 
dose profile and tumor conformed treatment.
This idea was first tested at the Lawrence Berkeley National 
Laboratory (LBNL) (12). At the time, the accelerators avail-
able were not powerful enough to treat deep-seated tumors. 
Advancement in accelerator technology coupled with improved 
medical imaging and computing made proton therapy a viable 
option for routine medical applications in the 1970s. However, it 
is only since the 1990s that patients started being treated in clini-
cal settings. The first hospital-based facility to treat patients was 
at Loma Linda, USA. Since protons are hadrons, proton therapy 
is also referred to as hadron therapy.
The use of ions increases target conformity on the basis of 
physics principles, i.e., the dose distribution. In this respect, 
carbon ions have a smaller lateral penumbra than protons, 
which may allow a better protection of normal tissue. Also, 
carbon ions have a higher linear energy transfer (LET) com-
pared to protons and photons, which directly correlates with 
a higher relative biological effectiveness (RBE). LET of carbon 
ion beams increases steadily as they pass through the body, 
reaching a maximum in the Bragg peak region: this property 
is an obvious therapeutic advantage when treating deep-seated 
tumors. Carbon ions are also more efficient in hypoxic tumors, 
which are resistant to both photon and proton radiation. The 
lower acute or late toxicity of carbon ions compared to protons 
leads to an enhanced quality of life both during and after cancer 
treatment (13).
The first dedicated carbon ion facility became operational in 
1994 at the Heavy-Ion Medical Accelerator Centre (HIMAC) in 
Japan (14, 15). In Europe, the first patient was treated with carbon 
ions at the Gesellschaft für Schwerionenforschung (GSI) labora-
tory in Darmstadt, Germany, in 1997 (16).
With the growing interest in particle therapy, the first dual ion 
(protons and carbon ions) clinical facility in Europe, established 
in Heidelberg, Germany, started treating patients at the end of 
2009. This was followed by CNAO in Pavia, Italy, which started 
treating patients in 2011. The third dual ion center in Europe at 
MedAustron in Wiener Neustadt, Austria, is expected to start 
treating patients in 2016.
CeRN AND PARTiCLe THeRAPY
CERN has been playing an active role in hadron therapy with the 
design of a dedicated synchrotron for protons and carbon ions 
(PIMMS) and the involvement in ENLIGHT. At present, efforts 
in hadron therapy are focused on establishing a facility to provide 
ion beams for research.
FiGURe 2 | CeRN’s accelerator chain. The proposed OPENMED facility would use beams from the existing LEIR machine.
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The Proton ion Medical Machine Study
The PIMMS group was formed following an agreement between 
the MedAustron (Austria) and the TERA Foundation (Italy) to 
combine their efforts in the design of a cancer therapy synchro-
tron. The study group was later joined by Onkologie 2000 (Czech 
Republic). CERN agreed to host this study in its PS Division; the 
PIMMS team started their work in January 1996, and continued 
working for a period of 3 years.
Proton Ion Medical Machine Study aimed at producing a 
synchrotron design optimized for treating cancer patients with 
protons and carbon ions. The proposed design was detailed in 
two reports issued in 2000 (17). The PIMMS concept was further 
enhanced by TERA, and implemented at CNAO and MedAustron. 
Except the initial design study, CERN has also contributed to the 
realization of the CNAO and MedAustron treatment centers, in 
particular with expertise in accelerators and magnets, and with 
training of personnel. Both projects have been accomplished 
through networks of national and international collaborations.
OPeN-Access MeDical Facility
The need for an open-access facility for R&D with ion beams in the 
context of medical applications was first raised at the ENLIGHT 
meeting in 2005 in Oropa, Italy. This was reiterated by a wide mul-
tidisciplinary scientific community at the 2010 Physics for Health 
workshop, where CERN was asked to take a lead on this initiative. 
In order to establish OPENMED (OPEN-Access MEDical Facility), 
the possibility of modifying the existing CERN low energy ion ring 
(LEIR) accelerator was evaluated in the open brainstorming ses-
sion in 2012. Again, the broad positive feedback from the medical 
and radiobiological communities was received (18).
OPEN-Access MEDical Facility intends to provide suitable 
ion beams for a multitude of interdisciplinary studies, including 
radiation biology, nuclear physics models for medicine, detectors 
and instrumentation for dosimetry, diagnostics, and imaging. 
OPENMED will complement a few existing or planned beam 
lines for this kind of multidisciplinary research, providing ample 
beam time without the constraints of a clinical setting. Ideally, all 
centers hosting research beam lines should form a pan-European 
collaborative network that will allocate beam time to researchers 
in an effective and concerted way.
The cost of establishing such a facility entirely dedicated to the 
R&D with ion beams for the medical community will be signifi-
cantly less at CERN than in a place that lacks the accelerator chain, 
the expertise to maintain it, and the general infrastructure needed 
to host the research purposes (see Figure 2). The project entails 
FiGURe 3 | The eNLiGHT network. Group picture of the participants to the 
2011 ENLIGHT meeting at the Marburg facility, which will start treating 
patients soon.
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modifications of the existing LEIR accelerator, which is currently 
being used for 1 month a year to inject heavy ions into the LHC. 
The beam energy and size, and its capability of providing up to 
9 months of beam time per year, make LEIR an ideal candidate for 
conversion into OPENMED, which will run without perturbing 
the scheduled LHC operation (19).
Research at OPENMED will make a significant contribution 
to the progress of medical physics, biomedical research, medical 
simulations, and the development of innovative detectors and 
beam instrumentation.
Studies at OPENMED will ultimately lead to a more safe, 
optimal, and cost-effective treatment of cancer with radiation. 
Medical and radiobiological collaborators will be able to investi-
gate the biological impact of different ion beams at various ener-
gies on tumor cells and biological materials, and then to optimize 
radiation therapy for different types of cancer. The research will 
be carried out on cell cultures and tissues, and it is not foreseen 
to conduct live animal or human experiments.
In fact, the impressive ion beam radiobiology experi-
ments have been performed over the past 50 years. They were 
fragmented in time and were performed with different beam 
qualities and cell systems. All of them need to be systematically 
reexplored in one single setting, under standardized dosimetry 
and laboratory conditions, in larger panels of biologically well-
characterized human cancer and normal tissue cell systems. 
The ultimate gain would be a comprehensive model that can 
individualize therapy, incorporating clinical, biological and 
physics inputs. Also, it is imperative to develop state-of-the-art 
instrumentation and methods to bring the performance of had-
ron therapy to the level of the most advanced photon therapy 
techniques. 
OPEN-Access MEDical Facility will offer ample opportuni-
ties for testing novel radiation detectors, medical instrumenta-
tion, optimized delivery of the therapeutic beam to patients, 
diagnostics, and dosimetry. The experimental verification and 
improvement of biological simulation models will also be pos-
sible, along with the studies of complex processes such as nuclear 
fragmentation.
Experiments at OPENMED will be selected by a panel of 
experts and carried out within the international collaborations, 
capitalizing on CERN’s culture of scientific openness, and attract-
ing experts from a variety of fields. OPENMED will become a hub 
for interdisciplinary exchange, offering R&D opportunities for 
research in medical radiation biology as well as for the develop-
ment of a wide portfolio of particle physics techniques, which 
may be translated into medical applications: detectors, simula-
tion, accelerators, simulation, data handling, and data analytics. 
These activities would complement other work elsewhere, and 
contribute to boost the impact of particle physics research on 
healthcare (20).
eNLiGHT – THe eUROPeAN NeTwORK 
FOR LiGHT iON HADRON THeRAPY
Hadron therapy is the epitome of a multidisciplinary and transna-
tional venture: its full development requires the competences of 
physicists, physicians, radiobiologists, engineers, and IT experts, 
as well as collaboration between research and industrial partners. 
ENLIGHT was established to co-ordinate European efforts in 
using ion beams for radiation therapy and to catalyze collabora-
tion and co-operation among the different disciplines involved 
(21). ENLIGHT had its inaugural meeting in February 2002 at 
CERN and was funded by the European Commission (EC) for its 
first 3 years (2002–2005).
Despite the end of EC funding in 2005, the following year the 
network members decided to maintain ENLIGHT alive, with the 
primary mandate to develop strategies to obtain the necessary 
funding for hadron therapy research, and to establish and imple-
ment common standards and protocols for treating patients. 
Since then, the co-ordination office has been run at CERN. The 
current membership exceeds 400 participants from more than 20 
countries across Europe.
While the network itself flourishes without the dedicated 
funding, the R&D activities have been funded primarily through 
EC projects.
Between 2008 and 2015, four EC projects have been started 
under the umbrella of ENLIGHT, for a total funding of 24 million 
Euro: PARTNER, ULICE, ENVISION and ENTERVISION. All 
these projects are directed toward different aspects of developing, 
establishing, and optimizing hadron therapy (22).
The Particle Training Network for European Radiotherapy 
(PARTNER) was a 4-year Marie Curie Training project aimed 
at educating young biologists, engineers, radio-oncologists, and 
physicists in the various aspects of hadron therapy. PARTNER 
provided research and training opportunities for 29 young 
scientists from a variety of backgrounds and countries between 
2008 and 2012, allowing them to actively develop modern tech-
niques for treating cancer in close collaboration with the leading 
European institutions.
The Union of Light Ion Centres in Europe (ULICE) was an 
infrastructure project which started in 2009 in response to a 
need for greater access to hadron therapy facilities for clinical 
and technological research (see Figure 3). The project was built 
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around three pillars: development of instruments and protocols; 
increasing co-operation between facilities and research communi-
ties within the research infrastructure; and transnational access to 
treatment centers.
A key challenge in particle therapy today is quality assurance 
during treatment, which needs advanced medical imaging tech-
niques. This issue has been tackled by the ENVISION project, 
which started in 2010 and covered developments in time-of-
flight in-beam PET, in-beam single particle tomography, organ 
motion monitoring techniques, simulation, and treatment plan-
ning. Additionally, ENVISION served as the training platform 
for ENTERVISION, a Marie-Curie Initial Training Network 
aimed at educating young researchers in online 3D digital 
imaging.
Future Priorities and Challenges
Since the annual meeting in summer 2014, the ENLIGHT 
community has started discussing the future of the network, 
in terms of both structure and scientific priorities. It is clear 
that the focus of R&D for hadron therapy has shifted since the 
birth of ENLIGHT. It is because the number of clinical centers 
(and especially centers with proton therapy) has dramatically 
increased (see Figures 4 and 5). Also, while technology devel-
opments are still needed in order to ensure increasing accuracy 
and more cost efficient treatment, further development of 
proton therapy is now solidly in the hands of industry. The 
advent of single-room facilities will bring proton therapy, 
albeit with some restrictions, to smaller hospitals and clinical 
centers.
From the clinical standpoint, a large number of facilities 
worldwide would allow the medical community to perform ran-
domized trials to optimize hadron therapy. However, it should be 
noted that there is a certain reluctance within the hadron therapy 
community to begin clinical trials from scratch, since a large 
number of patients has been now treated with both protons and 
carbon ions, with quite positive results for the main indications. 
In addition, most of the patients who contact a hadron therapy 
center are well informed about the treatment, and they expect to 
be treated with particles.
From the clinical standpoint, the major challenges for 
ENLIGHT in the coming years will be, on the clinical side, 
to catalyze collaborative efforts in defining a roadmap for 
randomized trials (23) and in studying the issue of RBE in 
details. The efforts concerning technology developments will 
be continued on quality assurance through imaging and on the 
design of compact accelerators and gantries for ions heavier 
than protons. Information technologies will take a central 
stage, since medical data sharing, data analytics, and decision 
support systems for patient and treatment selection are key 
topics.
FiGURe 4 | Hadron therapy centers in europe in 2002. This picture shows the distribution and number of hadron therapy centers when ENLIGHT was started.
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Providing training will be a major focus in the coming years, as 
the growing number of facilities requires more and more trained 
personnel: the aim will be to train professionals who are highly 
skilled in their specialty but at the same time are familiar with the 
multidisciplinary aspects of hadron therapy.
CONCLUSiON
Cross-fertilization between particle physics and medicine contin-
ues to be important for improved healthcare. This process needs 
to be fueled through multidisciplinary exchanges, and geared 
toward the needs of the medical community. Since 2014, CERN 
has begun structuring its medical applications activities and 
has established an international panel of medical and technical 
experts to assist the laboratory in setting priorities and choosing 
the future R&D directions.
This paper focuses on the activities related to hadron 
therapy. CERN has a tight bond with ENLIGHT, since the 
launch of the network in 2002. ENLIGHT has been very suc-
cessful in gathering funds for hadron therapy research across 
Europe and has catalyzed a number of successful projects 
and collaborations. At present, the ENLIGHT community is 
establishing a roadmap for the future, taking into account the 
FiGURe 5 | Hadron therapy centers in europe in September 2015. This picture shows the present distribution and number of hadron therapy centers.
changes that occurred in the hadron therapy landscape in the 
past few years.
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